<DOC>
	<DOCNO>NCT01734018</DOCNO>
	<brief_summary>This multicenter , prospective , observational study evaluate efficacy safety Pegasys ( peginterferon alfa-2a ) routine clinical practice patient HBeAg-positive HBeAg-negative chronic hepatitis B . Eligible patient receive treatment Pegasys accord standard care summary od product characteristics/local labelling follow duration treatment 2 year follow-up .</brief_summary>
	<brief_title>An Observational Study Pegasys ( Peginterferon Alfa-2a ) Patients With HBeAg-Positive HBeAg-Negative Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age HBeAgpositive HBeAgnegative serologically proven chronic hepatitis B without cirrhosis Elevated serum ALT &gt; ULN ( upper limit normal ) &lt; /=10 x ULN accord local label Contraindications Pegasys detail label Coinfection hepatitis A , hepatitis B HIV Concomitant therapy telbivudine ( concomitant peginterferon alfa2a therapy contraindicate accord telbivudine label ) Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>